Advertisement

Topics

Companies Related to "Prostate Cancer Patients OncBioMune Phase Clinical Trial ProscaVax" [Most Relevant Company Matches] - Page: 5 RSS

19:32 EDT 24th March 2019 | BioPortfolio

Here are the most relevant search results for "Prostate Cancer Patients OncBioMune Phase Clinical Trial ProscaVax" found in our extensive corporate database of over 50,000 company records.

Showing "Prostate Cancer Patients OncBioMune Phase Clinical Trial ProscaVax" Companies 101–125 of 9,500+

Relevant

Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers, including...


Access Pharmaceuticals, Inc.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug del...

Conkwest, Inc.

Conkwest is an innovative immuno-oncology company that is developing and commercializing a portfolio of highly potent and selective cellular therapies for the treatment of cancers and serious viral infections. Conkwest’s products are based on its proprietary cancer-killing cell line Neukoplast™ (also known as NK-92), the only known cell line that ...


Ångstrom Pharmaceuticals, Inc.

Ångstrom Pharmaceuticals, Inc. is a venture-backed pharmaceutical company. Ångstrom’s proprietary products target a clearly-defined pathway, the Urokinase Plasminogen Activation System (PA), which has repeatedly been shown in scientific literature to be directly involved in proliferative diseases, such as cancer and wet age-related macular degeneration (ARMD). The Company’s lead product, ...

Corvas International Incorporated

Corvas International, Inc. is a biopharmaceutical company focused on development of a new generation of drugs that address today's largest medical markets, cardiovascular disease and cancer, based on our expertise in vascular biology and protease modulation. We have a strategic alliance with Pfizer Inc for the development and commercialization of our novel anti-inflammatory agent (rNIF or UK-279,2...

GenVec

GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of our gene-based therapeutic product candidates use a common patent-protected technology platform to deliver genes that produce medically beneficial proteins directly at the site of disease. TNFerade™ represents a novel approach to treating cancer in combination with rad...

Biomira

Biomira Inc. (TSE: BRA; Nasdaq: BIOM) is a product focused biotechnology company applying its proprietary immunotherapy and organic chemistry technologies for the development of cancer therapeutics. The Company's lead product, THERATOPE® vaccine, is currently being tested in a Phase III clinical trial for metastatic breast cancer. The Company's commitment to the development of products for the ...

Clinical Network Services (CNS)

Clinical Network Services (CNS) Pty Ltd is an Australian CRO, focused on providing full contract research organisational clinical trial services to the international healthcare community particularly during the early phase (Phase I and Phase II) clinical development of their products. CNS has established itself as Brisbane’s only headquartered Australian CRO working both nationally with dedicat...

NeoRX Corporation

NeoRx Corporation develops innovative therapeutic biopharmaceuticals primarily for the treatment of cancer, cardiovascular, and inflammatory diseases. As part of its cancer treatment program, NeoRx is currently conducting a Phase I trial of its Skeletal Targeted Radiation ("STR") product combined with chemotherapy in patients with multiple myeloma. NeoRx is also developing a proprietary PRETARGET-...

VG Life Sciences Inc.

San Marino, California-based VG Life Sciences Inc., formerly known as Viral Genetics, discovers and develops drug therapies from two exclusively licensed platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). A physician-initiated Phase I clinical trial of an MDT compound in combination with Nexavar™ on...

Genexine, Inc.

Genexine, Inc., listed on KOSDAQ (095700) since 2009, is a leading biotherapeutics company focused on immuno-oncology and orphan disease. Genexine has robust pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA technology. In the clinical stage, Genexine has GX-H9 (long-acting human growth hormone, hGH...

Cancer Center of Boston

The Cancer Center of Boston was established in September 1986 by Jacob J. Lokich, MD and Murray M. Bern, MD, formerly the chiefs of medical oncology and hematology, respectively, at the New England Deaconess Hospital. Their collaboration was based on the desire to develop a network of community based, freestanding facilities to diagnose and treat cancer and hematologic diseases with state-of-the-a...

Harpoon Therapeutics, Inc.

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel T-cell recruiting d...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Introgen Therapeutics

Introgen Therapeutics (NASDAQ: INGN) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. We are developing product candidates to treat a wide range of cancers using non-integrating tumor suppressors, cytokines and genes. These agents are designed to increase production of normal c...

Biothera Pharmaceuticals Inc.

Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in tri...

GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC Biotech is also...

Oncura

On July 1, 2003, a merger between two innovative leaders in prostate cancer treatments set the standard for minimally invasive options. The merger between Amersham Health (now GE Healthcare)–Therapy Business, the leader in brachytherapy and Galil Medical’s Urology Business, the innovator in cryotherapy procedures was finalized. This formed a new company combining both our people and products e...

The German Breast Group and Celgene Corporation

GBG is a large independent academic network of over 500 study centers in Germany with the world- wide largest experience in conducting neoadjuvant breast cancer trials. Since 1998, with joined forces from AGO-B, over 10.000 patients participated in the neoadjuvant “Gepardo” trial series. GBG has recruited at totality of over 35.000 patients to tr...

Aurinia Pharmaceuticals Inc.

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal d...

Cure Forward and Symbiodx

Cure Forward is built on the desire to help patients identify and better understand relevant treatment options for their condition by bridging the gap for patients and precision medicine, beginning in cancer. Through our website, patients can become champions of their own care, work more effectively with care providers and make more informed choices ...

California Clinical Trials (CCT)

Since 1981 California Clinical Trials (CCT) has been at the forefront of drug development. Our best-in-class clinical experts, research staff, and trained physicians all work together seamlessly to bring hope to patients around the world. Our executive team comprises outstanding leaders in medical science. Whether you need careful patient selection for your Phase 1 studies, or experience in drug d...

TKL Research

TKL Research is a US-based clinical research services company offering complete Phase I-IV clinical trial services in several enrollment-driven therapeutic areas. These include dermatology, allergy/respiratory, diabetes, gastroenterology, and women's health. TKL also has 5 research clinics in the NY metropolitan area for single-center Phase I-IV clinical trials for pharmaceutical, biologic, medica...

Synexus Clinical Research plc

Synexus is the only multinational company specialising in the recruitment and management of patients in later stage clinical trials at its own specialist centres across the globe. Synexus was formed in 1998 when two leading UK clinical trial organisations, the Edgebright Partnership and the clinical trials division of AEA Technology Plc, merged.Today Synexus has experienced, high capacity clinica...

Direct Therapeutics, Inc.

Direct Therapeutics, Inc. is a development-stage pharmaceutical company using its patented Solvent-Facilitated Perfusion technology to create new drugs for the localized and regional treatment of solid-tumor cancers. Our products are designed for direct injection to target tissue with minimal invasion of healthy tissue. They contain active ingredients in organic solvent vehicles that facilitate th...


More From BioPortfolio on "Prostate Cancer Patients OncBioMune Phase Clinical Trial ProscaVax"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks